CTLA-4 抗体伊匹木单抗（Ipilimumab）已被证实具有临床获益，但由于其对外周调节性 T 细胞（Tregs）的影响，也存在不良反应。因此，选择性靶向肿瘤 ...

在一系列体外和体内实验中，CAR-TFoxp3细胞显示出更强的抗耗竭能力，能够更有效地抵抗肿瘤的多次刺激，并在移植瘤模型中显著抑制肿瘤生长，显示出更高的持久性和抗肿瘤效力。研究结果表明，CAR-TFoxp3细胞在肿瘤微环境中表现出的优势，依赖于Foxp3介导的代谢重塑。

CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum. 60 , 123–132 (2009). Article CAS Google Scholar ...

本研究针对ZFP36家族RNA结合蛋白(RBP)在调节性T细胞(Treg)中的功能空白，通过构建Treg特异性敲除小鼠模型，发现ZFP36L1/L2通过调控 ...

本研究针对ZFP36家族RNA结合蛋白(RBP)在调节性T细胞(Treg)中的功能空白，通过构建Treg特异性敲除小鼠模型，发现ZFP36L1/L2通过调控 ...

Agenus Inc. ("Agenus" or the Company") (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in ...

high affinity binding anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment (TME). Vilastobart is currently being ...

anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with ...

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed ... downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.